Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.74 per share a year ago.
Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
The biotech sector possesses a significant predicted Compounding Annual Growth Rate (CAGR) of 14% between 2023 to 2032. But the risks certainly match the rewards.
Big Money Eyes Halozyme for Strong Growth
A recent patent approval for biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) resulted in raised 2024 guidance.
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
Small biotech company Halozyme is behind some of the biggest names in medicine, including Johnson & Johnson's Darzalex and Roche's Tecentriq.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
